Sort
82,697 grants matching “vaccine development”
A Study of Protective Immunity Against Dengue in Infants
$679,824Daniel H. Libraty · Univ Of Massachusetts Med Sch Worcester · U01 · FY2007 · AI
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection
$679,799Mikell Paige · George Mason University · R01 · FY2023 · AI
Determinants of retroviral replication in non-native hosts for modeling HIV infection
$679,686Amit Sharma · Ohio State University · R56 · FY2022 · AI
Early Drivers of Humoral Immunity to SARS-CoV-2 Infections
$679,626Christopher L King · Case Western Reserve University · U01 · FY2022 · CA
Immune Function and Biodefense in Children, Elderly, and the Immunocrompromised
$679,595Hildegund C. J. Ertl · Wistar Institute · N01 · FY2010 · AI
Occurrence and Outcome of Dual HIV-1 Infection
$679,593James Ivan Mullins · University Of Washington · R37 · FY2012 · AI
mRNA-LNPs for ARDS
$679,571Hamideh Parhiz · University Of Pennsylvania · R01 · FY2023 · HL
Immunological characterization of the P. vivax DBP
$679,540John Adams · University Of South Florida · R01 · FY2014 · AI
The development of a recombinant vaccine against human onchocerciasis
$679,506Sara Lustigman · New York Blood Center · R01 · FY2011 · AI
Fenway Adolescent Trials Unit
$679,491Kenneth H Mayer · Fenway Community Health Center · U01 · FY2015 · HD
Core E - Regulatory Compliance Core
$679,447David Beasley · University Of Texas Med Br Galveston · UC7 · FY2025 · AI
Next Generation Resolution of Antiviral Gene Networks
$679,393Dusan Bogunovic · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · AI
Immunological characterization of the P. vivax DBP
$679,373John Adams · University Of South Florida · R01 · FY2009 · AI
HIV-TB Co-infection: Tracking TB emergence after asymptomatic (latent) infection
$679,336Philana Ling Lin · University Of Pittsburgh At Pittsburgh · R01 · FY2014 · AI
HIV-TB Co-infection: Tracking TB emergence after asymptomatic (latent) infection
$679,336Philana Ling Lin · University Of Pittsburgh At Pittsburgh · R01 · FY2015 · AI
Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE)
$679,332Michael Stephen Trent · University Of Georgia · R01 · FY2019 · AI
Western New England Maternal Pediatric Adolescent AIDS Clinical Trials Unit
$679,325Katherine F Luzuriaga · Univ Of Massachusetts Med Sch Worcester · UM1 · FY2013 · AI
Systems modeling to address the social and biological drivers of disparities in infection and mortality from emerging infectious diseases
$679,307Jonathan L Zelner · University Of Michigan At Ann Arbor · R01 · FY2022 · MD
Targeting the IL-2/regulatory T cell axis for autoimmune disease prevention in realistic animal models
$679,264Daniel J. Campbell · Benaroya Research Inst At Virginia Mason · R01 · FY2019 · AI
Targeting the IL-2/regulatory T cell axis for autoimmune disease prevention in realistic animal models
$679,264Daniel J. Campbell · Benaroya Research Inst At Virginia Mason · R01 · FY2022 · AI
Targeting the IL-2/regulatory T cell axis for autoimmune disease prevention in realistic animal models
$679,264Daniel J. Campbell · Benaroya Research Inst At Virginia Mason · R01 · FY2020 · AI
Targeting the IL-2/regulatory T cell axis for autoimmune disease prevention in realistic animal models
$679,264Daniel J. Campbell · Benaroya Research Inst At Virginia Mason · R01 · FY2021 · AI
Epidemiology of Helicobacter Pylori Transmission
$679,241Julie Parsonnet · Stanford University · R01 · FY2007 · AI
Evaluation of Memory Responses and Biomarkers from a Phase IEnterotoxigenic Escherichia coli (ETEC) Intramuscular SubunitVaccine with dmLT Adjuvant
$679,209Elizabeth B Norton · Tulane University Of Louisiana · R01 · FY2025 · AI
ALLOGENEIC TGF-B ANTISENSE CELL VACCINE FOR LUNG CANCER
$679,196Novarx Corporation · R44 · FY2004 · CA